Importance of Multidisciplinary Approach in Care of CAR-T MM Patients

Opinion
Video

This segment explores Dr. Rossi's clinical experience with cilta-cel as a second-line therapy, focusing on its efficacy and quality-of-life benefits across diverse patient populations.

Video content above is prompted by the following:

  • Can you share your experience with cilta-cel as a second-line therapy?
  • What advantages in terms of efficacy and quality of life have you noted across various patient populations?
Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
2 experts are featured in this series.
4 experts in this video
4 experts in this video
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content